RxDoctor Payments Data

Andreea Olaru, MD

Internal Medicine · Rosedale, MDNPI 1962684464

Payments from drug & device makers

$745in general payments, 2019–2025

Across 33 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$221
  • Lilly USA, LLC$94
  • Exact Sciences$90
  • Astellas Pharma US Inc$80
  • Dexcom, Inc.$67
  • Amgen$60
  • plus $133 from 4 others

What the payments were for

  • Food & beverage$67991%
  • Education$669%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$745 in reported general payments places this provider in the 65th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$113,609
Medicare patients
314
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$54,011
EliquisApixaban33$41,752
JardianceEmpagliflozin36$27,130
TrulicityDulaglutide13$24,624
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,108
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl56$5,796
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,125
Atorvastatin Calcium275$3,590
Rosuvastatin Calcium144$3,178
SynthroidLevothyroxine Sodium44$2,625
Losartan Potassium209$2,359
Amlodipine Besylate237$2,001
Gabapentin78$1,802
Ezetimibe32$1,674
Candesartan Cilexetil12$1,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$221$54,01138 claims
PfizerEliquis$38$41,75233 claims
Lilly USA, LLCTrulicity$94$24,62413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Rosedale

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →